Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Neuroleptic Malignant-Like Syndrome Due to Donepezil and Maprotiline
Neurol 60:1050-1051, Ohkoshi,N.,et al, 2003
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric symptoms and Functional Impairment in Alzheimer Disease
JAMA 289:210-216, Trinh,N.,et al, 2003
Acetylcholinesterase Inhibitors for Vascular Dementia and Alzheimer's Disease Combined With Cerebrovascular Disease
Stroke 34:584-586, Bowler,J.V., 2003
Donepezil in Vascular Dementia
Neurol 61:479-486,429, Helme,R.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Efficacy of Galantamine in Probable Vascular Dementia and Alzheimer's Disease Combined with Cerebrovascular Disease: A Randomised Trial
Lancet 359:1283-1290,1265, Erkinjuntti,T.,et al, 2002
Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Effect of Donepezil on Brain Acetylcholineserase Activity in Patients with AD Measured by PET
Neurol 56:408-410, Shinotoh,H.,et al, 2001
Drugs for Alzheimer's Disease
BMJ 323:123-124, O'Brien,J.T . &Ballard,C.G., 2001
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Pyridostigmine-Induced Microcephaly
Neurol 54:1873-1874, Niesen,C.E.&Shah,N.S., 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
Efficacy of Rivastigmine in Dementia with Lewy Bodies: a Randomised, Double-blind, Placebo-controlled International Study
Lancet, 356:2031-2036,2024, McKeith,I.,et al, 2000
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease
Neurol 52:1138-1145,1115, Neumann,P,J.,et al, 1999
Clinical Benefits of Donepezil:Results from a Long-Term Phase III Extension Trial
Neurol 52:A174, Doody,R.S.,et al, 1999
Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction
NEJM 341:137-141, Ponec,R.J.,et al, 1999
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Donepezil Improves Cognition & Global Function in Alzheimer Dis, 15-Week Doub-Blind, Plac-Contr Study
Arch Int Med 158:1021-1031, 9411998., Rogers,S.L.,et al, 1998
Metrifonate Benefits Cognitive, Behvioral, and Global Function in Patients with Alzheimer's Disease
Neurol 50:1222-1230, 12031998., Morris,J.C.,et al, 1998
Metrifonate Treatment of the Cognitive Deficits of Alzheimer's Disease
Neurol 50:1214-1221, 12031998., Cummings,J.L.,et al, 1998
Dementia with Lewy Bodies:Response of Delirium-Like Features to Donepezil
Neurol 51:1512, Kaufer,D.I.,et al, 1998
A 24-Week, Double-Blind, Placebo-Controlled Trial of Donepezil in Pts with Alzheimer's Disease
Neurol 50:136-145, Rogers,S.,et al, 1998
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
JAMA 278:1363-1371, Small,G.W.,et al, 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997
Clinical Experience with Donepezil Hydrochloride:A Case Study Perspective
Advan Therapy 14:305-311, Geldmacher,D.S., 1997
Drug Treatment of Alzheimer's Disease, Raise Clinical and Ethical Problems
BMJ 314:693-694, Kelley,C.A.,et al, 1997
Self-Reported Exposure to Neurotoxic Chemical Combinations in the Gulf War:A Cross-Sectional Epidemiologic Study
JAMA 227:231-237, 2591997., Haley,R.W.&Kurt,T.L., 1997
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
Long-Term Tacrine (Cognex) Treatment:Effects on Nursing Home Placement and Mortality
Neurol 47:166-177, Knopman,D.,et al, 1996
Tacrine
Lancet 345:625-630, Davis,K.L.&Powchik,P., 1995
The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Efficacy of Tacrine and Lecthin in Mild to Moderate Alzheimer's Disease:Double Blind Trial
BMJ 308:879-883, Maltby,N.,et al, 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Nerve Agents:A Review
Neurol 42:946-950, Gunderson,C.H.,et al, 1992
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Dissease
NEJM 327:1253-1259, 13061992., Davis,K.L.,et al, 1992